...
...
Next Story

Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO

The candidate vaccine developed by the Oxford University and the Serum Institute of India is among the two such vaccines added to the ongoing Ebola clinical trials, according to a World Health Organisation (WHO) statement, making it the first addition of candidate vaccines to the trials specifically targeting the Bundibugyo virus that has caused the current Ebola outbreak in the Democratic Republic of the Congo (DRC).

Published on: Nov 17, 2026, 07:38:30 IST
Advertisement

The candidate vaccine developed by the Oxford University and the Serum Institute of India is among the two such vaccines added to the ongoing Ebola clinical trials, according to a World Health Organisation (WHO) statement, making it the first addition of candidate vaccines to the trials specifically targeting the Bundibugyo virus that has caused the current Ebola outbreak in the Democratic Republic of the Congo (DRC).

India News
India News

“Expert groups convened by the World Health Organization (WHO) have recommended adding two new Ebola vaccine candidates to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC). The recommendation marks the first time vaccines specifically designed to protect against Bundibugyo virus, the virus responsible for the current outbreak, will be evaluated during an outbreak of the disease,” said WHO in a statement.

The two vaccine candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469. WHO’s independent Technical Advisory Group on Candidate Vaccine Prioritization has recommended both for further clinical evaluation this week, based on available preclinical and early clinical evidence. The companies were informed on Monday. The vaccine candidates will enter the trial following national approvals, the UN Health body announced.

The Institut National de Recherche Biomédicale, the DRC’s national public health and biomedical research institute is leading the vaccines trial, with support from the University of Antwerp, Belgium, WHO, Epicentre, Médecins Sans Frontières, the Institute of Tropical Medicine of Antwerp, and the Africa Centres for Disease Control and Prevention. The rapid development of candidate vaccines is made possible by investments by the Coalition for Epidemic Preparedness Innovations.

Tumaini is designed to test multiple vaccine candidates within a single trial, using a ring-vaccination approach that enrols contacts of people with confirmed Bundibugyo virus disease.

“It builds on an approach pioneered by WHO and partners during the West Africa Ebola outbreak a decade ago, when a landmark trial in Guinea established the efficacy of Ervebo against Ebola virus, also known as Zaire ebolavirus. Ervebo is the first vaccine being evaluated in a Tumaini trial to now assess efficacy against Bundibugyo virus,” read the WHO statement.

It added that four vaccination rings are already in place, with several more being prepared. The rings include contacts of people who became ill or died from Ebola.

“Research into potential treatments is also advancing. The WHO-sponsored PARTNERS trial, launched in July, is evaluating whether the monoclonal antibody MBP134, the antiviral remdesivir, or a combination of both can improve survival among patients with confirmed Bundibugyo virus disease. In addition, maftivimab will soon be added to the trial to assess its use as a potential treatment,” said WHO.

A complementary post-exposure prophylaxis study with Obeldesivir is also underway.

“WHO is supporting research during the Bundibugyo virus disease outbreak through its R&D Blueprint and Health Emergencies Programme, including developing research protocols, providing strategic and technical advice, coordinating among partners, and providing operational support to embed rigorous and ethical studies within the response,” said WHO.

Initial findings from the treatment trials are expected in the coming months, with results from the vaccine trial expected in early 2027.

 
ABOUT THE AUTHOR
Rhythma Kaul

Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.

Get Latest News, breaking headlines, and top India News, and today real-time updates from across the nation. Stay informed on politics, government policies, crime, Today Weather, and major developments on Hindustan Times
Get Latest News, breaking headlines, and top India News, and today real-time updates from across the nation. Stay informed on politics, government policies, crime, Today Weather, and major developments on Hindustan Times
SHARE THIS ARTICLE ON
Notifications

Get breaking alerts directly from the newsroom

Notifications are on!You'll be notified when news breaks